Item 1.01. Entry into a Material Definitive Agreement.

On November 13, 2019, Eidos Therapeutics, Inc. ("Eidos"), a partially-owned subsidiary of BridgeBio Pharma, Inc. (the "Company"), and Silicon Valley Bank (the "Bank") and Hercules Capital, Inc. ("Hercules" and together with Bank, the "Lenders"), entered into a Loan and Security Agreement (the "Loan Agreement"). Under the Loan Agreement, the Lenders will loan to Eidos up to $55,000,000 (the "Term Loan"). As of September 30, 2019, the Company owned 66.3% of the outstanding common stock of Eidos.

The maturity date for the Term Loan is October 2, 2023 (the "Maturity Date"). The interest rate for the Term Loan is a floating per annum rate equal to greater of (a) 8.5% and (b) 3.25% above the Wall Street Journal Prime Rate. The Loan Agreement requires Eidos to make monthly interest only payments until November 1, 2021 and this interest only period may be extended to May 2, 2022 upon meeting a clinical data milestone by September 30, 2021.

The final payment on the Term Loan, due on the Maturity Date, shall include all outstanding principal and accrued and unpaid interest under the Term Loan, plus a final payment (the "Final Payment") equal to the original aggregate principal amount of the Term Loan multiplied by 5.95%. Once repaid, amounts borrowed under the Term Loan may not be reborrowed. Eidos may prepay the Term Loan, subject to paying a prepayment fee as set forth in the agreement and the Final Payment.

The Loan Agreement requires Eidos to pay an aggregate non-refundable commitment fee of $275,000 and reimburse certain Lenders' expenses. The Loan Agreement also requires Eidos to make and maintain certain customary financial covenants, representations and warranties and other agreements. The Loan Agreement also contains customary events of default, including non-payment of principal or interest, violations of covenants, bankruptcy and material judgments. Eidos' obligations to the Lenders are secured by substantially all of Eidos' assets, excluding intellectual property.

Eidos intends to use any proceeds from the Term Loan for general corporate purposes.

The foregoing description of the Term Loan is only a summary and is qualified in its entirety by reference to the Loan Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.




Item 8.01. Other Events.

On November 16, 2019, the Company issued a press release titled, "BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures" (the "Press Release"). A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
  No.                                   Description

10.1†       Loan and Security Agreement dated November  13, 2019 between Eidos
          Therapeutics, Inc., a partially owned subsidiary of Registrant, as
          borrower, Silicon Valley Bank and Hercules Capital, Inc., together as
          lenders.

99.1        Press release dated November 16, 2019.

† Portions of this exhibit have been omitted as confidential information.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses